--- title: "TCC Case Study: Sir Oliver" description: Sir Oliver, an 8 year old French Bulldog with TCC, is surviving and thriving thanks to his targeted therapeutic treatment 4.5 months from FidoCure™ enrollment, Sir Oliver's latest CT scan showed a 38% reduction in his bladder tumor. image: https://blog.fidocure.com/hubfs/oliver-1-1.jpg --- [![FidoCure](https://blog.fidocure.com/hs-fs/hubfs/fidocure_logo.png?width=296&height=68&name=fidocure_logo.png "FidoCure")](https://www.fidocure.com/) - [Veterinarians](https://fidocure.com/for-veterinarians/) - [Portal Login](https://dvm.fidocure.com/) - [Veterinary Blog](https://blog.fidocure.com/fidocure-blog/tag/vet) - [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies) - [Webinars](https://blog.fidocure.com/fidocure-blog/tag/webinars) - [Pet Parents](https://fidocure.com/pet-parents/) - [About Us](https://fidocure.com/about-us/) - [How it works](https://fidocure.com/how-it-works/) - [Find a Clinic](https://fidocure.com/find-a-clinic/) - [Contact Us](https://fidocure.com/contact-us/) [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies) # TCC Case Study: Sir Oliver [Dr. Gerry Post](https://blog.fidocure.com/fidocure-blog/author/dr-gerry-post) [Share this blog post on Twitter](https://twitter.com/intent/tweet?text=I+found+this+interesting+blog+post&url=https://blog.fidocure.com/fidocure-blog/tcc-case-study-sir-oliver) [Share this blog post on Facebook](http://www.facebook.com/share.php?u=https://blog.fidocure.com/fidocure-blog/tcc-case-study-sir-oliver) [Share this blog post on LinkedIn](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.fidocure.com/fidocure-blog/tcc-case-study-sir-oliver) #### Sir Oliver, an 8 year old French Bulldog with TCC, is surviving and thriving thanks to his targeted therapeutic treatment4.5 months from FidoCure™ enrollment, Sir Oliver's latest CT scan showed a 38% reduction in his bladder tumor. Sir Oliver, an 8 year old French Bulldog with TCC, is surviving and thriving thanks to his targeted therapeutic treatment 4.5 months from FidoCure™ enrollment, Sir Oliver's latest CT scan showed a 38% reduction in his bladder tumor. We are excited to share with you another one of our FidoCure™ canine cancer warriors. Sir Oliver Heymers, an 8-year old French Bulldog, is surviving and thriving, thanks to his targeted therapeutic, trametinib, a MAP2K1 and MAP2K2 inhibitor. His latest CT scan showed a reduction in his bladder tumor by 38%, 4.5 months following FidoCure™ enrollment. Sir Oliver presented to his veterinarian in November, 2018, with hematuria. Tumor cells were found in his urinalysis sample and he was diagnosed with transitional cell carcinoma (TCC). TCC is a malignant tumor of the urinary bladder that often arises from the trigone of the bladder, making surgical removal extremely difficult. Only approximately 30% of TCCs respond to traditional chemotherapy, so we are thrilled to have this result with a targeted therapy. When Sir Oliver was diagnosed with TCC, his family and veterinarian elected to enroll in FidoCure™ and treat him with targeted therapy. Sir Oliver’s response has been phenomenal and his family reports he is “acting years younger” and they are “finally really seeing a difference in him”. In addition, the hematuria has almost completely resolved. Nothing makes us happier than to see a targeted therapy option create a significant impact on quantity and quality of life for patients. The data we collected in Sir Oliver’s case will help future dogs, and ultimately, humans, receive better, more personalized, cancer care. ## Related Articles [![](https://blog.fidocure.com/hubfs/Imported_Blog_Media/Mental_Health_in_the_Veterinary_Community_Age_of_Covid19.png)](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/mental-health-in-the-veterinary-community-in-the-age-of-covid-19/amp) ### [Mental Health in the Veterinary Community in the Age of COVID-19](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/mental-health-in-the-veterinary-community-in-the-age-of-covid-19/amp) Mental health for veterinary professionals can be a challenge in the best of times and even more so during the stressful COVID-19 pandemic. Many of us are concerned with... [Dr. Gerry Post](https://blog.fidocure.com/fidocure-blog/author/dr-gerry-post) [Read More](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/mental-health-in-the-veterinary-community-in-the-age-of-covid-19/amp) [![](https://blog.fidocure.com/hubfs/Imported_Blog_Media/literature_support_for_targeted_therapy.png)](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/literature-support-for-targeted-therapy/amp) ### [Literature Support for Targeted Therapy](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/literature-support-for-targeted-therapy/amp) In recent academic literature, there have been more and more publications documenting that biochemical pathways in canine cancer cells are often dysregulated, and... [Dr. Gerry Post](https://blog.fidocure.com/fidocure-blog/author/dr-gerry-post) [Read More](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/literature-support-for-targeted-therapy/amp) ![fc_portal_logo_bw](https://blog.fidocure.com/hubfs/fc_portal_logo_bw.svg) - [How it Works](https://fidocure.com/how-it-works/) - [FAQ](https://fidocure.com/faq/) - [Contact Us](https://fidocurestg.wpengine.com/contact-us/) - [For Vets](https://fidocure.com/for-veterinarians/) - [About Us](https://fidocure.com/about-us/) - [Terms of Service](https://fidocure.com/terms-of-service/) - [Blog](https://blog.fidocure.com/fidocure-blog) - [Careers](https://fidocure.com/careers/) - [Privacy Policy](https://fidocure.com/privacy-policy/) - - - - **FidoCure® is an advanced cancer-care service for dogs, developed by One Health Company**. DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.  © Copyright 2018-2026 One Health Company, All rights reserved ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Dr. Gerry Post", "url" : "https://blog.fidocure.com/fidocure-blog/author/dr-gerry-post" }, "dateModified" : "2023-05-09T15:51:31.583Z", "datePublished" : "2023-05-04T17:45:21.000Z", "headline" : "TCC Case Study: Sir Oliver", "image" : [ "https://blog.fidocure.com/hubfs/oliver-1-1.jpg" ], "mainEntityOfPage" : { "@id" : "https://blog.fidocure.com/fidocure-blog/tcc-case-study-sir-oliver", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.fidocure.com/hubfs/fidocure_logo.png" }, "name" : "FidoCure" } } ```